- Q3 2026 Net loss reached $20.3M ($0.32/share) vs. $16.9M R&D and $5.3M G&A expenses
- Cash, cash equivalents and securities stood at $208.6M at quarter-end
- Regulatory plan update for DT-216P2 expected in Q4 2026 with 12-week data in Q1 2027
Why is $DSGN moving today? · SEC 8-K archive
$DSGN SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $DSGN: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $DSGN filing catalyst
Why did $DSGN trigger an AI stock catalyst alert?
$DSGN triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -0.5/10). Headline: Design Therapeutics Reports Q3 Net Loss of $20.3M, Cash at $208.6M. Key points: - Q3 2026 Net loss reached $20.3M ($0.32/share) vs. $16.9M R&D and $5.3M G&A expenses - Cash, cash equivalents and securities stood at $208.6M at quarter-end - Regulatory plan update for DT-216P2 expected in Q4 2026 with 12-week data in Q1 2027
How did $DSGN stock react after the SEC filing?
After the SEC 8-K for $DSGN, observed market reaction: T0 price $10.63. Past moves do not guarantee future results.
Where can I get real-time $DSGN SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $DSGN via Telegram and the VIP Web Terminal from €10/month.